Abbott Laboratories Targets 70-80M CGM Users with Nutrition, Electrophysiology Growth
Abbott Laboratories forecasts accelerating second-half growth driven by Nutrition, electrophysiology and core lab diagnostics following its Q1 earnings. CEO Robert Ford introduced conservative full-year guidance due to a weaker respiratory season while highlighting MedTech strength, CGM expansion to 70-80 million potential users and seamless Exact Sciences integration.
1. Q1 Earnings Overview
Abbott Laboratories reported robust Q1 performance, fueled by strategic gains in Nutrition, electrophysiology and core lab diagnostics. Management expressed confidence in accelerating growth in the second half based on product launches and expanded commercial initiatives.
2. Conservative Full-Year Guidance
CEO Robert Ford outlined a slightly conservative full-year outlook reflecting a softer-than-expected respiratory season. He noted that respiratory testing is not anticipated to recover strongly in Q4, but MedTech and pharmaceuticals are projected to sustain solid momentum.
3. Exact Sciences Integration
Abbott has integrated Exact Sciences into its comparable growth metrics to present a unified portfolio view. Management emphasized efforts to expand Cologuard’s domestic and international penetration and leverage potential guideline changes to broaden the screening population.
4. CGM Market Outlook
Abbott estimates a global continuous glucose monitoring market of 70-80 million users, supported by upcoming reimbursement for type 2 non-insulin users and international rollout. The company is preparing for dual analyte system approval to sustain its competitive advantage through innovation and cost leadership.